Published in Neurobiol Dis on April 01, 2004
Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci (2007) 2.81
Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol (2007) 2.18
Cerebral white matter integrity and cognitive aging: contributions from diffusion tensor imaging. Neuropsychol Rev (2009) 2.05
Advances in white matter imaging: a review of in vivo magnetic resonance methodologies and their applicability to the study of development and aging. Neurosci Biobehav Rev (2006) 1.77
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage (2007) 1.41
White matter damage of patients with Alzheimer's disease correlated with the decreased cognitive function. Surg Radiol Anat (2006) 1.24
Quantitative cortical mapping of fractional anisotropy in developing rat brains. J Neurosci (2008) 1.22
DTI abnormalities in anterior corpus callosum of rats with spike-wave epilepsy. Neuroimage (2009) 1.13
Associations between white matter hyperintensities and β amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One (2013) 1.03
Associations between white matter microstructure and amyloid burden in preclinical Alzheimer's disease: A multimodal imaging investigation. Neuroimage Clin (2014) 1.02
Hypoxic injury during neonatal development in murine brain: correlation between in vivo DTI findings and behavioral assessment. Cereb Cortex (2009) 1.00
Diffusion tensor imaging of cocaine-treated rodents. Psychiatry Res (2009) 0.99
Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev (2009) 0.97
Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol (2010) 0.96
Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol (2012) 0.95
Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement (2012) 0.91
Cellular correlates of longitudinal diffusion tensor imaging of axonal degeneration following hypoxic-ischemic cerebral infarction in neonatal rats. Neuroimage Clin (2014) 0.89
Neuroimaging biomarkers of epileptogenesis. Neurosci Lett (2011) 0.89
In vivo imaging of tau pathology using multi-parametric quantitative MRI. Neuroimage (2015) 0.87
Current neuroimaging techniques in Alzheimer's disease and applications in animal models. Am J Nucl Med Mol Imaging (2012) 0.85
Diffusion tensor imaging detects retinal ganglion cell axon damage in the mouse model of optic nerve crush. Invest Ophthalmol Vis Sci (2011) 0.85
The fornix in mild cognitive impairment and Alzheimer's disease. Front Aging Neurosci (2015) 0.83
The impact of myelination on axon sparing and locomotor function recovery in spinal cord injury assessed using diffusion tensor imaging. NMR Biomed (2013) 0.83
Magnetic resonance imaging (MRI) as a translational tool for the study of neonatal stroke. J Child Neurol (2011) 0.81
Longitudinal Assessment of Amyloid Pathology in Transgenic ArcAβ Mice Using Multi-Parametric Magnetic Resonance Imaging. PLoS One (2013) 0.81
Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiol Aging (2015) 0.80
Fiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease. J Aging Res (2011) 0.80
Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiol Aging (2016) 0.80
In vivo quantitative whole-brain diffusion tensor imaging analysis of APP/PS1 transgenic mice using voxel-based and atlas-based methods. Neuroradiology (2013) 0.80
Brain fiber tract plasticity in experimental spinal cord injury: diffusion tensor imaging. Exp Neurol (2008) 0.80
An Alzheimer's disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia (2011) 0.79
Improvements in a Mouse Model of Alzheimer's Disease Through SOD2 Overexpression are Due to Functional and Not Structural Alterations. Magn Reson Insights (2012) 0.78
Atlas-based diffusion tensor imaging correlates of executive function. J Alzheimers Dis (2015) 0.78
In vivo diffusion tensor imaging of amyloid-β-induced white matter damage in mice. J Alzheimers Dis (2014) 0.78
In vivo imaging biomarkers in mouse models of Alzheimer's disease: are we lost in translation or breaking through? Int J Alzheimers Dis (2010) 0.78
Diffusion tensor magnetic resonance imaging of the brain in APP transgenic mice: a cohort study. PLoS One (2013) 0.78
Phase-aligned multiple spin-echo averaging: a simple way to improve signal-to-noise ratio of in vivo mouse spinal cord diffusion tensor image. Magn Reson Imaging (2014) 0.78
Altered whole-brain white matter networks in preclinical Alzheimer's disease. Neuroimage Clin (2015) 0.77
Axonal Terminals Exposed to Amyloid-β May Not Lead to Pre-Synaptic Axonal Damage. J Alzheimers Dis (2015) 0.76
The fornix provides multiple biomarkers to characterize circuit disruption in a mouse model of Alzheimer's disease. Neuroimage (2016) 0.75
Genetic and environmental influences on cortical mean diffusivity. Neuroimage (2016) 0.75
Preclinical Magnetic Resonance Imaging and Spectroscopy Studies of Memory, Aging, and Cognitive Decline. Front Aging Neurosci (2016) 0.75
Structural and metabolic changes in the traumatically injured rat brain: high-resolution in vivo proton magnetic resonance spectroscopy at 7 T. Neuroradiology (2017) 0.75
White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiol Aging (2017) 0.75
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage (2003) 8.47
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage (2005) 7.24
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med (2007) 3.40
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry (2006) 2.05
Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron (2009) 2.03
Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest (2008) 2.01
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem (2006) 1.98
Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med (2011) 1.97
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem (2005) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci (2005) 1.90
Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A (2007) 1.89
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. Brain (2010) 1.80
Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. J Neurotrauma (2007) 1.79
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia. Ann Neurol (2003) 1.78
Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed (2008) 1.78
Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis (2002) 1.74
Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One (2011) 1.74
Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol (2007) 1.70
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 1.68
Lysosomal sorting of amyloid-β by the SORLA receptor is impaired by a familial Alzheimer's disease mutation. Sci Transl Med (2014) 1.67
Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis (2006) 1.67
Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci (2006) 1.65
The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J Biol Chem (2005) 1.63
Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol (2006) 1.60
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. JAMA Neurol (2013) 1.60
YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry (2010) 1.59
SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58
Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci (2003) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest (2013) 1.57
Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol (2002) 1.53
Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci (2011) 1.53
Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J Biol Chem (2006) 1.53
Dynamic analysis of amyloid β-protein in behaving mice reveals opposing changes in ISF versus parenchymal Aβ during age-related plaque formation. J Neurosci (2011) 1.53
Role of caspase-3 in ethanol-induced developmental neurodegeneration. Neurobiol Dis (2005) 1.52
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. Arch Neurol (2012) 1.52
Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol (2011) 1.51
SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J Neurosci (2010) 1.51
ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc Natl Acad Sci U S A (2013) 1.50
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol (2011) 1.50
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
Evaluation of 5-ethynyl-2'-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system. Brain Res (2010) 1.50
Neuronal activity regulates extracellular tau in vivo. J Exp Med (2014) 1.48